Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin vs Empagliflozin in T2D on DPP-4 Inhibitor
NCT03351478Phase 3Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Nov 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of sotagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoint: Change From Baseline in Hemoglobin A1c at 26 weeks. Started Nov 2017; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03351478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351478.